Clinical Trial Update: Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib in patients with Type B3 thymoma or thymic carcinoma in second and later lines; status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Type B3 Thymoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Type B3 Thymoma, Thymic Carcinoma | Phase 2 | Status: UNKNOWN